Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV neurocognitive disorders: a randomized clinical trial of central nervous system (CNS)- targeted highly active antiretroviral therapy (HAART).

Next Previous
Search
Trial Profile

HIV neurocognitive disorders: a randomized clinical trial of central nervous system (CNS)- targeted highly active antiretroviral therapy (HAART).

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir; Amprenavir; Antiretrovirals; Atazanavir; Darunavir; Delavirdine; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Enfuvirtide; Etravirine; Fosamprenavir; Lamivudine; Lamivudine/abacavir; Lamivudine/zidovudine; Lamivudine/zidovudine/abacavir; Lopinavir/ritonavir; Maraviroc; Nelfinavir; Nevirapine; Raltegravir; Ritonavir; Saquinavir; Tenofovir disoproxil fumarate; Tipranavir; Zidovudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms CIT2

    • Most Recent Events

    • 23 Apr 2014 Biomarkers information updated
    • 04 Mar 2013 Primary endpoint 'Cognitive-function' has not been met.
    • 04 Mar 2013 Primary endpoint 'Assessment-scale-scores' has not been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top